{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.47","value":"-1.7"},{"groupId":"OG001","spread":"0.47","value":"-2.4"},{"groupId":"OG002","spread":"0.50","value":"-1.6"}]}],"title":"Change from Baseline at Week 1 [N=63; 63; 57]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.62","value":"-4.0"},{"groupId":"OG001","spread":"0.62","value":"-5.2"},{"groupId":"OG002","spread":"0.66","value":"-4.4"}]}],"title":"Change from Baseline at Week 4 [N=63; 62; 58]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.68","value":"-5.0"},{"groupId":"OG001","spread":"0.68","value":"-6.3"},{"groupId":"OG002","spread":"0.73","value":"-5.3"}]}],"title":"Change from Baseline at Week 8 [N=62; 63; 56]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.83","value":"-5.2"},{"groupId":"OG001","spread":"0.81","value":"-6.3"},{"groupId":"OG002","spread":"0.89","value":"-4.8"}]}],"title":"Change from Baseline at Week 12 [N=58; 61; 52]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.78","value":"-5.0"},{"groupId":"OG001","spread":"0.77","value":"-6.2"},{"groupId":"OG002","spread":"0.83","value":"-4.8"}]}],"title":"Change from Baseline at EOT [N=63; 64; 58]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"The IPSS is a validated global questionnaire used to assess the degree of \"bother\" from benign prostatic hyperplasia symptoms and is based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic).\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at baseline \\& 1 or both at any postbaseline on-treatment visit. End of treatment (EOT) includes the last on-treatment assessment for patients who didn't complete Week 12; N is the number of patients included.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 1, 4, 8 and 12","title":"Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Total Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}